Welcome to our Knowledge Hub

The biopharmaceutical manufacturing landscape is undergoing a profound transformation, driven by the rise of personalized therapies, particularly in Cell and Gene Therapeutics. This revolutionary shift is not only redefining the products being developed but also necessitating a complete overhaul of production tools and processes.

In cell culture, two primary growth methods exist: adherent culture and suspension culture. The choice between these methods depends on cell type, application, and scalability needs. While adherent cells require attachment to a surface for growth, suspension cells freely float in liquid media. Each approach has its unique advantages, limitations, and specific cultivation requirements.

The successful commercialization of cell and gene therapies (CGTs) depends on the ability to scale production efficiently while maintaining product consistency, safety, and regulatory compliance. A well-designed bioreactor scale-up strategy is critical in ensuring that processes developed in early-stage research can transition seamlessly into commercial-scale biomanufacturing.

The life science tools sector, particularly bioreactor technologies, is emerging as a high-growth investment frontier in Europe, combining scientific innovation with robust market dynamics. Driven by pandemic-era acceleration and sustained demand for biopharmaceuticals, this sector offers compelling opportunities for venture capital (VC) and institutional investors. Here's why bioreactors and related technologies are poised to deliver strong returns while advancing global hea

In the development and manufacture of advanced biopharmaceuticals—including cell and gene therapies—cell expansion is a critical step that directly influences yield, quality, and consistency of the final product. Maintaining a viable and productive cell population requires precise control over multiple parameters within the bioreactor environment. Among these, dissolved oxygen (DO) concentration in the liquid phase stands out as a critical process parameter (CPP).

Bioreactors are essential tools in biotechnology, enabling controlled environments for cell culture, fermentation, and metabolite production. Their role is crucial in biopharmaceutical manufacturing, regenerative medicine, and large-scale cell expansion. As bioprocessing demands grow, bioreactor scale-up becomes a key challenge, ensuring that laboratory-developed processes translate effectively into industrial-scale production.

In recent years, Germany’s role in biotech has evolved, particularly in cell and gene therapy manufacturing, where its strong GMP expertise is both an asset and a challenge. While Germany remains a key hub for innovation, complex bureaucracy, extensive documentation requirements, and rigid GMP standards have made scaling advanced therapies slow and costly.

Stem cell cultivation of iPSCs and MSCs is essential to ensure scalability for regenerative medicine and advanced therapies.

Working together for a sustainable future: Bürkert Fluid Control Systems and Green Elephant Biotech